Comparing BeOne Medicines (NASDAQ:ONC) & ProKidney (NASDAQ:PROK)

BeOne Medicines (NASDAQ:ONC) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for BeOne Medicines and ProKidney, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1	2	11	1	2.80
ProKidney	2	1	4	1	2.50

BeOne Medicines presently has a consensus price target of $389.15, indicating a potential upside of 26.05%. ProKidney has a consensus price target of $7.40, indicating a potential upside of 337.87%. Given ProKidney’s higher probable upside, analysts clearly believe ProKidney is more favorable than BeOne Medicines.

Profitability

This table compares BeOne Medicines and ProKidney’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
ProKidney	-8,131.50%	N/A	-21.39%

Volatility & Risk

BeOne Medicines has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.

Earnings & Valuation

This table compares BeOne Medicines and ProKidney”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.74 billion	5.90	$286.93 million	$4.47	69.07
ProKidney	$890,000.00	573.31	-$68.99 million	($0.53)	-3.19

BeOne Medicines has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

48.5% of BeOne Medicines shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

BeOne Medicines beats ProKidney on 9 of the 14 factors compared between the two stocks.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.